— Know what they know.
Not Investment Advice

TRAX NASDAQ

First Tracks Biotherapeutics Inc
1W: +19.9% 1M: +26.3% 3M: +3.9% YTD: +128.8%
$45.38
+1.90 (+4.37%)
After Hours: $45.50 (+0.12, +0.26%)
Weekly Expected Move ±11.8%
$34 $39 $44 $49 $54
NASDAQ · Healthcare · Biotechnology · Tech Score Buy · Power 65 · $1.6B mcap · 31M float · 2.90% daily turnover · Short 51% of daily vol
Credit Risk of going bust: not rated Debt: 0.3% of company value Bonds: none of note held by US funds details ▾
Not rated: insufficient price history.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$1.6B
52W Range14.72-49.91
Volume592,253
Avg Volume888,934
Beta3.37
Dividend—
Analyst Ratings
9 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEODaniel R. Faga
Employees104
SectorHealthcare
IndustryBiotechnology
IPO Date2026-04-20
10770 Wateridge Circle
San Diego, CA 92121
US
858 362 6295
About First Tracks Biotherapeutics Inc

First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.

Recent Insider Trades

NameTypeSharesPriceDate
ANAPTYSBIO, INC J-Other 100 — 2026-04-20
ANAPTYSBIO, INC 0 — 2026-04-01

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms